Dissolution Kinetics of a BCS Class II Active Pharmaceutical Ingredient: Diffusion-Based Model Validation and Prediction

Dissolution Kinetics of a BCS Class II Active Pharmaceutical Ingredient: Diffusion-Based Model Validation and Prediction

Bibliographic Details
Main Authors:	Yuan Gao, Brian Glennon, Yunliang He, Philip Donnellan
Format:	Article
Language:	English
Published:	American Chemical Society 2021-03-01
Series:	ACS Omega
Online Access:	https://doi.org/10.1021/acsomega.0c05558

Similar Items

DISSOLUTION PROFILE STUDIES OF BCS CLASS II DRUG VALSARTAN BY BIOWAIVER PROCEDURE
by: E. R. Brigas, et al.
Published: (2019-01-01)

Study of the effect of active pharmaceutical ingredients of various classes of BCS on the parameters of thermosensitive systems based on poloxamers
by: E.O. Bakhrushina, et al.
Published: (2023-10-01)

Recent solubility and dissolution enhancement techniques for repaglinide a BCS class II drug: a review
by: Saba Albetawi, et al.
Published: (2021-08-01)

Solubility, Permeability, and Dissolution Rate of Naftidrofuryl Oxalate Based on BCS Criteria
by: Marta Kus-Slowinska, et al.
Published: (2020-12-01)

Analysis of spironolactone polymorphs in active pharmaceutical ingredients and their effect on tablet dissolution profiles
by: Renata Cunha de Resende, et al.

Equilibrium solubility study to determine fexofenadine hydrochloride BCS class and challenges in establishing conditions for dissolution profiles applied to suspension
by: Lorena de Sousa Rosa, et al.
Published: (2020-11-01)

Development of Robust Tablet Formulations with Enhanced Drug Dissolution Profiles from Centrifugally-Spun Micro-Fibrous Solid Dispersions of Itraconazole, a BCS Class II Drug
by: Stefania Marano, et al.
Published: (2023-03-01)

Equilibrium solubility versus intrinsic dissolution: characterization of lamivudine, stavudine and zidovudine for BCS classification
by: André Bersani Dezani, et al.
Published: (2013-12-01)

EVALUATION OF THE PRESENCE OF POLYMORPHIC FORMS AND INFLUENCE ON THE DISSOLUTION PROFILE OF TENOXICAM IN ACTIVE PHARMACEUTICAL INGREDIENT AND FORMULATIONS
by: Aline Taís Fries, et al.
Published: (2018-12-01)

EVALUATION OF THE PRESENCE OF POLYMORPHIC FORMS AND INFLUENCE ON THE DISSOLUTION PROFILE OF TENOXICAM IN ACTIVE PHARMACEUTICAL INGREDIENT AND FORMULATIONS
by: Aline Taís Fries, et al.
Published: (2018-12-01)

EVALUATION OF THE PRESENCE OF POLYMORPHIC FORMS AND INFLUENCE ON THE DISSOLUTION PROFILE OF TENOXICAM IN ACTIVE PHARMACEUTICAL INGREDIENT AND FORMULATIONS
by: Aline Taís Fries, et al.
Published: (2018-12-01)

EVALUATION OF THE PRESENCE OF POLYMORPHIC FORMS AND INFLUENCE ON THE DISSOLUTION PROFILE OF TENOXICAM IN ACTIVE PHARMACEUTICAL INGREDIENT AND FORMULATIONS
by: Aline Taís Fries, et al.
Published: (2018-12-01)

EVALUATION OF THE PRESENCE OF POLYMORPHIC FORMS AND INFLUENCE ON THE DISSOLUTION PROFILE OF TENOXICAM IN ACTIVE PHARMACEUTICAL INGREDIENT AND FORMULATIONS
by: Aline Taís Fries, et al.
Published: (2018-12-01)

Bio Pharmaceutics Classification System (BCS) Class IV Drug Nanoparticles: Quantum Leap to Improve Their Therapeutic Index
by: Sachin Kumar, et al.
Published: (2018-11-01)

Batch Crystallization of Active Pharmaceutical Ingredient: Kinetics and Equilibrium Modelling
by: Marko Trampuž, et al.
Published: (2018-12-01)

Lipid nanoparticles: A challenging approach for oral delivery of BCS Class-II drugs
by: Ganesan Poovi, et al.
Published: (2018-12-01)

An In Vivo Predictive Dissolution Methodology (iPD Methodology) with a BCS Class IIb Drug Can Predict the In Vivo Bioequivalence Results: Etoricoxib Products
by: Isabel Gonzalez-Alvarez, et al.
Published: (2021-04-01)

Binary Mixtures of Some Active Pharmaceutical Ingredients with Fatty Alcohols—The Criteria of Successful Eutectic Formation and Dissolution Improvement
by: Songhee Jin, et al.
Published: (2020-11-01)

Feasibility analysis of using a bubble column evaporator as a solvent swap device
by: Darren Cappelli, et al.
Published: (2022-06-01)

The kinetics of dissolution of some II-VI semiconductor compounds.
by: Locker, Laurence David
Published: (2005)

Lipid Based Formulations of Biopharmaceutics Classification System (BCS) Class II Drugs: Strategy, Formulations, Methods and Saturation
by: Šoltýsová I., et al.
Published: (2016-12-01)

Novel active pharmaceutical ingredients from India: The issues—part-II
by: Prasanta Kumar Ghosh
Published: (2021-01-01)

Development and Evaluation of Lactose-Free Single-Unit and Multiple-Unit Preparations of a BCS Class II Drug, Rivaroxaban
by: Daniel Zakowiecki, et al.
Published: (2024-11-01)

New non-toxic biocompatible dianionic ionic liquids that enhance the solubility of oral drugs from BCS class II
by: Daniela A.S. Agostinho, et al.
Published: (2021-09-01)

CHEMICAL ENGINEERING IN THE PHARMACEUTICAL INDUSTRY : Active Pharmaceutical Ingredients /
by: Ende, David J. Am, editor, et al.
Published: (2019)

EFFECT OF PRE-CALVING BCS ON POSTPARTUM BCS AND BODY WEIGHT CHANGE OF SAHIWAL CATTLE
by: V. Sharma, et al.
Published: (2019-12-01)

THE KINETICS OF CALCITE DISSOLUTION PRECIPITATION
by: Brown, C, et al.
Published: (1993)

Vaterite Dissolution: Mechanism and Kinetics
by: Milner, MP, et al.
Published: (2024)

Kinetics of electrochemical metal dissolution /
by: 294393 Kiss, Laszlo
Published: (1987)

Development and Evaluation of Self-Emulsifying Drug-Delivery System–Based Tablets for Simvastatin, a BCS Class II Drug
by: Bashir MA, et al.
Published: (2023-01-01)

Optimisation of a Greener-Approach for the Synthesis of Cyclodextrin-Based Nanosponges for the Solubility Enhancement of Domperidone, a BCS Class II Drug
by: Mohit Vij, et al.
Published: (2023-04-01)

Investigation of the effect of solubility increase at the main absorption site on bioavailability of BCS class II drug (risperidone) using liquisolid technique
by: Ahmed Khames
Published: (2017-01-01)

Handling of highly active pharmaceutical ingredients and intermediates in the pharmaceutical industry
by: David Miedinger
Published: (2022-01-01)

BCS glossary of computing and ICT /
by: British Computer Society, et al.
Published: (2008)

Kinetic Optimization of the Batch Crystallization of an Active Pharmaceutical Ingredient in the Presence of a Low-Solubility, Precipitating Impurity
by: Mitchell Paolello, et al.
Published: (2023-11-01)

Nano-hydroxyapatite improves intestinal absorption of acetazolamide (BCS Class IV drug)-but how?
by: Kenichi Kaneko, et al.
Published: (2022-01-01)

Investigating Halloysite Nanotubes as a Potential Platform for Oral Modified Delivery of Different BCS Class Drugs: Characterization, Optimization, and Evaluation of Drug Release Kinetics
by: Husain T, et al.
Published: (2021-03-01)

Different BCS Class II Drug-Gelucire Solid Dispersions Prepared by Spray Congealing: Evaluation of Solid State Properties and In Vitro Performances
by: Serena Bertoni, et al.
Published: (2020-06-01)

Intestinal absorption of BCS class II drugs administered as nanoparticles: A review based on in vivo data from intestinal perfusion models
by: David Dahlgren, et al.
Published: (2020-09-01)

A Design of Experiment (DoE) based approach for development and optimization of nanosuspensions of telmisartan, a BCS class II antihypertensive drug
by: E. Bhargav, et al.
Published: (2020-05-01)